Stock Price & Volume | Full Chart
30-Day Implied Volatility | IV30 Full Chart
No headlines found.
Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update
PRNewswire (Mon, 13-Feb 4:15 PM ET)
Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 13, 2023
PRNewswire (Mon, 6-Feb 8:01 AM ET)
Aethlon Medical to Present at Sequire Biotechnology Conference on February 2nd, 2023
PRNewswire (Tue, 31-Jan 8:01 AM ET)
Aethlon Medical Announces Contract with NAMSA to Advance Hemopurifier Clinical Programs in Cancer
PRNewswire (Mon, 30-Jan 8:01 AM ET)
Aethlon Medical Inc is a medical technology company. It is focused on addressing unmet needs in health and biodefense. The company operates through two segments namely Aethlon for therapeutic applications, which represents its therapeutic business activities and ESI for diagnostic applications which signifies diagnostic business activities. It is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and to eliminate life-threatening viruses from the circulatory system. The company generates revenue from Aethlon segment.
Aethlon Medical trades on the NASDAQ stock market under the symbol AEMD.
As of March 27, 2023, AEMD stock price declined to $0.37 with 39,190 million shares trading.
AEMD has a beta of 1.58, meaning it tends to be more sensitive to market movements. AEMD has a correlation of 0.10 to the broad based SPY ETF.
AEMD has a market cap of $8.50 million. This is considered a Sub-Micro Cap stock.
Last quarter Aethlon Medical reported $0 in Revenue and -$.12 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.04.
In the last 3 years, AEMD stock traded as high as $12.49 and as low as $.23.
The top ETF exchange traded funds that AEMD belongs to (by Net Assets): VXF, ITOT.
AEMD has underperformed the market in the last year with a price return of -74.8% while the SPY ETF lost -10.5%. However, in the short term, AEMD had mixed performance relative to the market. It has outperformed in the last 3 months, returning +47.4% vs +4.0% return in SPY. But in the last 2 weeks, AEMD shares have been beat by the market, returning -8.6% compared to an SPY return of +3.2%.
AEMD support price is $.36 and resistance is $.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AEMD stock will trade within this expected range on the day.